AFM-24I is under clinical development by Affimed and currently in Phase II for Lung Cancer. According to GlobalData, Phase II drugs for Lung Cancer have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AFM-24I’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AFM-24I is under development for the treatment of solid tumors including but not limited to colorectal cancer, head and neck cancer squamous cell carcinoma, lung cancer, gastroesophageal (GE) junction carcinomas, biliary tract cancer, metastatic hepatocellular carcinoma and metastatic colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, cervical cancer, urothelial cancer, renal cell carcinoma, and glioblastoma multiforme. The drug candidate is a bi-specific monoclonal antibody act by targeting NK-cell via its CD16A receptor and tumor-specific wild type epidermal growth factor receptor (EGFR). FM-24 is a bi-specific, tetravalent human antibody. The drug candidate is developed based on Redirected Optimized Cell Killing (ROCK) platform. It is administered through intravenous route.
Affimed, a subsidiary of Affimed NV, is a pharmaceutical company that discovers and develops immunotherapies to treat hematologic cancers and solid tumors. The company is investigating AFM13, an innate cell engager, for the treatment of Peripheral T cell lymphoma, transformed mycosis fungoides, CD30-positive T cell lymphoma and Hodgkin’s lymphoma; AFM24, against solid tumors; AFM-26, targeting B-cell maturation antigen to treat multiple myeloma. It generates multi-specific antibodies to kill tumor cells and treat cancers through its ROCK platform technology. The company works in partnership with Amphivena Therapeutics Inc, Merck & Co Inc, Genentech Inc, AbCheck SRO and other companies to advance its pipeline. Affimed is headquartered in Mannheim, Baden-Wurttemberg, Germany
For a complete picture of AFM-24I’s drug-specific PTSR and LoA scores, buy the report here.